Drug major Lupin on Friday reported 11.92% decline in consolidated net profit to ₹529.75 crore for the quarter ended December, hit by weak sales in the US. Net sales, however, rose to ₹3,357.66 crore compared with ₹3,144.91 crore in the same period a year ago. Further, in the domestic market, the company’s sales grew by 17.1% to ₹871.2 crore.